Citigroup Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $59
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Yigal Nochomovitz maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lowers the price target from $62 to $59.
Citigroup analyst Yigal Nochomovitz maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lowers the price target from $62 to $59.